 | • レポートコード：MRC2-11QY06115 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は進行性骨化性線維異形成症治療薬のグローバル市場について調査・分析したレポートです。種類別（LJPC-6417、ジピリダモール、REGN-2477、その他）市場規模、用途別（病院、診療所、研究センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別進行性骨化性線維異形成症治療薬の競争状況、市場シェア ・世界の進行性骨化性線維異形成症治療薬市場：種類別市場規模 2015年-2020年（LJPC-6417、ジピリダモール、REGN-2477、その他） ・世界の進行性骨化性線維異形成症治療薬市場：種類別市場規模予測 2021年-2026年（LJPC-6417、ジピリダモール、REGN-2477、その他） ・世界の進行性骨化性線維異形成症治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、研究センター） ・世界の進行性骨化性線維異形成症治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、研究センター） ・北米の進行性骨化性線維異形成症治療薬市場分析：米国、カナダ ・ヨーロッパの進行性骨化性線維異形成症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの進行性骨化性線維異形成症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の進行性骨化性線維異形成症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの進行性骨化性線維異形成症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca Plc、Blueprint Medicines Corp、Clementia Pharmaceuticals Inc、Daiichi Sankyo Company Ltd、La Jolla Pharmaceutical Company、Oncodesign SA、Pfizer Inc、Regeneron Pharmaceuticals Inc ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Fibrodysplasia Ossificans Progressiva Drug Market
The global Fibrodysplasia Ossificans Progressiva Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Fibrodysplasia Ossificans Progressiva Drug Scope and Market Size
Fibrodysplasia Ossificans Progressiva Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Fibrodysplasia Ossificans Progressiva Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Fibrodysplasia Ossificans Progressiva Drug market is segmented into
LJPC-6417
Dipyridamole
REGN-2477
Others
Segment by Application, the Fibrodysplasia Ossificans Progressiva Drug market is segmented into
Hospital
Clinic
Research Center
Regional and Country-level Analysis
The Fibrodysplasia Ossificans Progressiva Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Fibrodysplasia Ossificans Progressiva Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Fibrodysplasia Ossificans Progressiva Drug Market Share Analysis
Fibrodysplasia Ossificans Progressiva Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Fibrodysplasia Ossificans Progressiva Drug business, the date to enter into the Fibrodysplasia Ossificans Progressiva Drug market, Fibrodysplasia Ossificans Progressiva Drug product introduction, recent developments, etc.
The major vendors covered:
AstraZeneca Plc
Blueprint Medicines Corp
Clementia Pharmaceuticals Inc
Daiichi Sankyo Company Ltd
La Jolla Pharmaceutical Company
Oncodesign SA
Pfizer Inc
Regeneron Pharmaceuticals Inc
1 Study Coverage
1.1 Fibrodysplasia Ossificans Progressiva Drug Product Introduction
1.2 Market Segments
1.3 Key Fibrodysplasia Ossificans Progressiva Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Fibrodysplasia Ossificans Progressiva Drug Market Size Growth Rate by Type
1.4.2 LJPC-6417
1.4.3 Dipyridamole
1.4.4 REGN-2477
1.4.5 Others
1.5 Market by Application
1.5.1 Global Fibrodysplasia Ossificans Progressiva Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Research Center
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Fibrodysplasia Ossificans Progressiva Drug Market Size, Estimates and Forecasts
2.1.1 Global Fibrodysplasia Ossificans Progressiva Drug Revenue 2015-2026
2.1.2 Global Fibrodysplasia Ossificans Progressiva Drug Sales 2015-2026
2.2 Global Fibrodysplasia Ossificans Progressiva Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Fibrodysplasia Ossificans Progressiva Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Fibrodysplasia Ossificans Progressiva Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Fibrodysplasia Ossificans Progressiva Drug Competitor Landscape by Players
3.1 Fibrodysplasia Ossificans Progressiva Drug Sales by Manufacturers
3.1.1 Fibrodysplasia Ossificans Progressiva Drug Sales by Manufacturers (2015-2020)
3.1.2 Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Fibrodysplasia Ossificans Progressiva Drug Revenue by Manufacturers
3.2.1 Fibrodysplasia Ossificans Progressiva Drug Revenue by Manufacturers (2015-2020)
3.2.2 Fibrodysplasia Ossificans Progressiva Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Fibrodysplasia Ossificans Progressiva Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Fibrodysplasia Ossificans Progressiva Drug Revenue in 2019
3.2.5 Global Fibrodysplasia Ossificans Progressiva Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Fibrodysplasia Ossificans Progressiva Drug Price by Manufacturers
3.4 Fibrodysplasia Ossificans Progressiva Drug Manufacturing Base Distribution, Product Types
3.4.1 Fibrodysplasia Ossificans Progressiva Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Fibrodysplasia Ossificans Progressiva Drug Product Type
3.4.3 Date of International Manufacturers Enter into Fibrodysplasia Ossificans Progressiva Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Fibrodysplasia Ossificans Progressiva Drug Market Size by Type (2015-2020)
4.1.1 Global Fibrodysplasia Ossificans Progressiva Drug Sales by Type (2015-2020)
4.1.2 Global Fibrodysplasia Ossificans Progressiva Drug Revenue by Type (2015-2020)
4.1.3 Fibrodysplasia Ossificans Progressiva Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Fibrodysplasia Ossificans Progressiva Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Fibrodysplasia Ossificans Progressiva Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Fibrodysplasia Ossificans Progressiva Drug Revenue Forecast by Type (2021-2026)
4.2.3 Fibrodysplasia Ossificans Progressiva Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Fibrodysplasia Ossificans Progressiva Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Fibrodysplasia Ossificans Progressiva Drug Market Size by Application (2015-2020)
5.1.1 Global Fibrodysplasia Ossificans Progressiva Drug Sales by Application (2015-2020)
5.1.2 Global Fibrodysplasia Ossificans Progressiva Drug Revenue by Application (2015-2020)
5.1.3 Fibrodysplasia Ossificans Progressiva Drug Price by Application (2015-2020)
5.2 Fibrodysplasia Ossificans Progressiva Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Fibrodysplasia Ossificans Progressiva Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Fibrodysplasia Ossificans Progressiva Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Fibrodysplasia Ossificans Progressiva Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Fibrodysplasia Ossificans Progressiva Drug by Country
6.1.1 North America Fibrodysplasia Ossificans Progressiva Drug Sales by Country
6.1.2 North America Fibrodysplasia Ossificans Progressiva Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Fibrodysplasia Ossificans Progressiva Drug Market Facts & Figures by Type
6.3 North America Fibrodysplasia Ossificans Progressiva Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Fibrodysplasia Ossificans Progressiva Drug by Country
7.1.1 Europe Fibrodysplasia Ossificans Progressiva Drug Sales by Country
7.1.2 Europe Fibrodysplasia Ossificans Progressiva Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Fibrodysplasia Ossificans Progressiva Drug Market Facts & Figures by Type
7.3 Europe Fibrodysplasia Ossificans Progressiva Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Fibrodysplasia Ossificans Progressiva Drug by Region
8.1.1 Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Sales by Region
8.1.2 Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Market Facts & Figures by Type
8.3 Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Fibrodysplasia Ossificans Progressiva Drug by Country
9.1.1 Latin America Fibrodysplasia Ossificans Progressiva Drug Sales by Country
9.1.2 Latin America Fibrodysplasia Ossificans Progressiva Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Fibrodysplasia Ossificans Progressiva Drug Market Facts & Figures by Type
9.3 Central & South America Fibrodysplasia Ossificans Progressiva Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug by Country
10.1.1 Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Sales by Country
10.1.2 Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Market Facts & Figures by Type
10.3 Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Market Facts & Figures by Application
11 Company Profiles
11.1 AstraZeneca Plc
11.1.1 AstraZeneca Plc Corporation Information
11.1.2 AstraZeneca Plc Description and Business Overview
11.1.3 AstraZeneca Plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Plc Fibrodysplasia Ossificans Progressiva Drug Products Offered
11.1.5 AstraZeneca Plc Related Developments
11.2 Blueprint Medicines Corp
11.2.1 Blueprint Medicines Corp Corporation Information
11.2.2 Blueprint Medicines Corp Description and Business Overview
11.2.3 Blueprint Medicines Corp Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Blueprint Medicines Corp Fibrodysplasia Ossificans Progressiva Drug Products Offered
11.2.5 Blueprint Medicines Corp Related Developments
11.3 Clementia Pharmaceuticals Inc
11.3.1 Clementia Pharmaceuticals Inc Corporation Information
11.3.2 Clementia Pharmaceuticals Inc Description and Business Overview
11.3.3 Clementia Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Clementia Pharmaceuticals Inc Fibrodysplasia Ossificans Progressiva Drug Products Offered
11.3.5 Clementia Pharmaceuticals Inc Related Developments
11.4 Daiichi Sankyo Company Ltd
11.4.1 Daiichi Sankyo Company Ltd Corporation Information
11.4.2 Daiichi Sankyo Company Ltd Description and Business Overview
11.4.3 Daiichi Sankyo Company Ltd Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Daiichi Sankyo Company Ltd Fibrodysplasia Ossificans Progressiva Drug Products Offered
11.4.5 Daiichi Sankyo Company Ltd Related Developments
11.5 La Jolla Pharmaceutical Company
11.5.1 La Jolla Pharmaceutical Company Corporation Information
11.5.2 La Jolla Pharmaceutical Company Description and Business Overview
11.5.3 La Jolla Pharmaceutical Company Sales, Revenue and Gross Margin (2015-2020)
11.5.4 La Jolla Pharmaceutical Company Fibrodysplasia Ossificans Progressiva Drug Products Offered
11.5.5 La Jolla Pharmaceutical Company Related Developments
11.6 Oncodesign SA
11.6.1 Oncodesign SA Corporation Information
11.6.2 Oncodesign SA Description and Business Overview
11.6.3 Oncodesign SA Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Oncodesign SA Fibrodysplasia Ossificans Progressiva Drug Products Offered
11.6.5 Oncodesign SA Related Developments
11.7 Pfizer Inc
11.7.1 Pfizer Inc Corporation Information
11.7.2 Pfizer Inc Description and Business Overview
11.7.3 Pfizer Inc Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Pfizer Inc Fibrodysplasia Ossificans Progressiva Drug Products Offered
11.7.5 Pfizer Inc Related Developments
11.8 Regeneron Pharmaceuticals Inc
11.8.1 Regeneron Pharmaceuticals Inc Corporation Information
11.8.2 Regeneron Pharmaceuticals Inc Description and Business Overview
11.8.3 Regeneron Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Regeneron Pharmaceuticals Inc Fibrodysplasia Ossificans Progressiva Drug Products Offered
11.8.5 Regeneron Pharmaceuticals Inc Related Developments
11.1 AstraZeneca Plc
11.1.1 AstraZeneca Plc Corporation Information
11.1.2 AstraZeneca Plc Description and Business Overview
11.1.3 AstraZeneca Plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Plc Fibrodysplasia Ossificans Progressiva Drug Products Offered
11.1.5 AstraZeneca Plc Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Fibrodysplasia Ossificans Progressiva Drug Market Estimates and Projections by Region
12.1.1 Global Fibrodysplasia Ossificans Progressiva Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Fibrodysplasia Ossificans Progressiva Drug Revenue Forecast by Regions 2021-2026
12.2 North America Fibrodysplasia Ossificans Progressiva Drug Market Size Forecast (2021-2026)
12.2.1 North America: Fibrodysplasia Ossificans Progressiva Drug Sales Forecast (2021-2026)
12.2.2 North America: Fibrodysplasia Ossificans Progressiva Drug Revenue Forecast (2021-2026)
12.2.3 North America: Fibrodysplasia Ossificans Progressiva Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Fibrodysplasia Ossificans Progressiva Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Fibrodysplasia Ossificans Progressiva Drug Sales Forecast (2021-2026)
12.3.2 Europe: Fibrodysplasia Ossificans Progressiva Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Fibrodysplasia Ossificans Progressiva Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Fibrodysplasia Ossificans Progressiva Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Fibrodysplasia Ossificans Progressiva Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Fibrodysplasia Ossificans Progressiva Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Fibrodysplasia Ossificans Progressiva Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Fibrodysplasia Ossificans Progressiva Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Fibrodysplasia Ossificans Progressiva Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Fibrodysplasia Ossificans Progressiva Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Fibrodysplasia Ossificans Progressiva Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Fibrodysplasia Ossificans Progressiva Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Fibrodysplasia Ossificans Progressiva Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Fibrodysplasia Ossificans Progressiva Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Fibrodysplasia Ossificans Progressiva Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Fibrodysplasia Ossificans Progressiva Drug Market Segments
Table 2. Ranking of Global Top Fibrodysplasia Ossificans Progressiva Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Fibrodysplasia Ossificans Progressiva Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of LJPC-6417
Table 5. Major Manufacturers of Dipyridamole
Table 6. Major Manufacturers of REGN-2477
Table 7. Major Manufacturers of Others
Table 8. Global Fibrodysplasia Ossificans Progressiva Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 9. Global Fibrodysplasia Ossificans Progressiva Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 10. Global Fibrodysplasia Ossificans Progressiva Drug Sales by Regions 2015-2020 (K Pcs)
Table 11. Global Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Regions (2015-2020)
Table 12. Global Fibrodysplasia Ossificans Progressiva Drug Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Fibrodysplasia Ossificans Progressiva Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 14. Global Fibrodysplasia Ossificans Progressiva Drug Sales Share by Manufacturers (2015-2020)
Table 15. Global Fibrodysplasia Ossificans Progressiva Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Fibrodysplasia Ossificans Progressiva Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Fibrodysplasia Ossificans Progressiva Drug as of 2019)
Table 17. Fibrodysplasia Ossificans Progressiva Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Fibrodysplasia Ossificans Progressiva Drug Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Fibrodysplasia Ossificans Progressiva Drug Price (2015-2020) (USD/Pcs)
Table 20. Fibrodysplasia Ossificans Progressiva Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Fibrodysplasia Ossificans Progressiva Drug Product Type
Table 22. Date of International Manufacturers Enter into Fibrodysplasia Ossificans Progressiva Drug Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Fibrodysplasia Ossificans Progressiva Drug Sales by Type (2015-2020) (K Pcs)
Table 25. Global Fibrodysplasia Ossificans Progressiva Drug Sales Share by Type (2015-2020)
Table 26. Global Fibrodysplasia Ossificans Progressiva Drug Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Fibrodysplasia Ossificans Progressiva Drug Revenue Share by Type (2015-2020)
Table 28. Fibrodysplasia Ossificans Progressiva Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 29. Global Fibrodysplasia Ossificans Progressiva Drug Sales by Application (2015-2020) (K Pcs)
Table 30. Global Fibrodysplasia Ossificans Progressiva Drug Sales Share by Application (2015-2020)
Table 31. North America Fibrodysplasia Ossificans Progressiva Drug Sales by Country (2015-2020) (K Pcs)
Table 32. North America Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Country (2015-2020)
Table 33. North America Fibrodysplasia Ossificans Progressiva Drug Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Country (2015-2020)
Table 35. North America Fibrodysplasia Ossificans Progressiva Drug Sales by Type (2015-2020) (K Pcs)
Table 36. North America Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Type (2015-2020)
Table 37. North America Fibrodysplasia Ossificans Progressiva Drug Sales by Application (2015-2020) (K Pcs)
Table 38. North America Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Application (2015-2020)
Table 39. Europe Fibrodysplasia Ossificans Progressiva Drug Sales by Country (2015-2020) (K Pcs)
Table 40. Europe Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Country (2015-2020)
Table 41. Europe Fibrodysplasia Ossificans Progressiva Drug Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Country (2015-2020)
Table 43. Europe Fibrodysplasia Ossificans Progressiva Drug Sales by Type (2015-2020) (K Pcs)
Table 44. Europe Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Type (2015-2020)
Table 45. Europe Fibrodysplasia Ossificans Progressiva Drug Sales by Application (2015-2020) (K Pcs)
Table 46. Europe Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Sales by Region (2015-2020) (K Pcs)
Table 48. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Sales by Type (2015-2020) (K Pcs)
Table 52. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Sales by Application (2015-2020) (K Pcs)
Table 54. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Application (2015-2020)
Table 55. Latin America Fibrodysplasia Ossificans Progressiva Drug Sales by Country (2015-2020) (K Pcs)
Table 56. Latin America Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Fibrodysplasia Ossificans Progressiva Drug Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Country (2015-2020)
Table 59. Latin America Fibrodysplasia Ossificans Progressiva Drug Sales by Type (2015-2020) (K Pcs)
Table 60. Latin America Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Type (2015-2020)
Table 61. Latin America Fibrodysplasia Ossificans Progressiva Drug Sales by Application (2015-2020) (K Pcs)
Table 62. Latin America Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Sales by Country (2015-2020) (K Pcs)
Table 64. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Sales by Type (2015-2020) (K Pcs)
Table 68. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Sales by Application (2015-2020) (K Pcs)
Table 70. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Application (2015-2020)
Table 71. AstraZeneca Plc Corporation Information
Table 72. AstraZeneca Plc Description and Major Businesses
Table 73. AstraZeneca Plc Fibrodysplasia Ossificans Progressiva Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 74. AstraZeneca Plc Product
Table 75. AstraZeneca Plc Recent Development
Table 76. Blueprint Medicines Corp Corporation Information
Table 77. Blueprint Medicines Corp Description and Major Businesses
Table 78. Blueprint Medicines Corp Fibrodysplasia Ossificans Progressiva Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 79. Blueprint Medicines Corp Product
Table 80. Blueprint Medicines Corp Recent Development
Table 81. Clementia Pharmaceuticals Inc Corporation Information
Table 82. Clementia Pharmaceuticals Inc Description and Major Businesses
Table 83. Clementia Pharmaceuticals Inc Fibrodysplasia Ossificans Progressiva Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 84. Clementia Pharmaceuticals Inc Product
Table 85. Clementia Pharmaceuticals Inc Recent Development
Table 86. Daiichi Sankyo Company Ltd Corporation Information
Table 87. Daiichi Sankyo Company Ltd Description and Major Businesses
Table 88. Daiichi Sankyo Company Ltd Fibrodysplasia Ossificans Progressiva Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 89. Daiichi Sankyo Company Ltd Product
Table 90. Daiichi Sankyo Company Ltd Recent Development
Table 91. La Jolla Pharmaceutical Company Corporation Information
Table 92. La Jolla Pharmaceutical Company Description and Major Businesses
Table 93. La Jolla Pharmaceutical Company Fibrodysplasia Ossificans Progressiva Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 94. La Jolla Pharmaceutical Company Product
Table 95. La Jolla Pharmaceutical Company Recent Development
Table 96. Oncodesign SA Corporation Information
Table 97. Oncodesign SA Description and Major Businesses
Table 98. Oncodesign SA Fibrodysplasia Ossificans Progressiva Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 99. Oncodesign SA Product
Table 100. Oncodesign SA Recent Development
Table 101. Pfizer Inc Corporation Information
Table 102. Pfizer Inc Description and Major Businesses
Table 103. Pfizer Inc Fibrodysplasia Ossificans Progressiva Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 104. Pfizer Inc Product
Table 105. Pfizer Inc Recent Development
Table 106. Regeneron Pharmaceuticals Inc Corporation Information
Table 107. Regeneron Pharmaceuticals Inc Description and Major Businesses
Table 108. Regeneron Pharmaceuticals Inc Fibrodysplasia Ossificans Progressiva Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 109. Regeneron Pharmaceuticals Inc Product
Table 110. Regeneron Pharmaceuticals Inc Recent Development
Table 111. Global Fibrodysplasia Ossificans Progressiva Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 112. Global Fibrodysplasia Ossificans Progressiva Drug Sales Market Share Forecast by Regions (2021-2026)
Table 113. Global Fibrodysplasia Ossificans Progressiva Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 114. Global Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 115. North America: Fibrodysplasia Ossificans Progressiva Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 116. North America: Fibrodysplasia Ossificans Progressiva Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 117. Europe: Fibrodysplasia Ossificans Progressiva Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 118. Europe: Fibrodysplasia Ossificans Progressiva Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 119. Asia Pacific: Fibrodysplasia Ossificans Progressiva Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 120. Asia Pacific: Fibrodysplasia Ossificans Progressiva Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 121. Latin America: Fibrodysplasia Ossificans Progressiva Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 122. Latin America: Fibrodysplasia Ossificans Progressiva Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 123. Middle East and Africa: Fibrodysplasia Ossificans Progressiva Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 124. Middle East and Africa: Fibrodysplasia Ossificans Progressiva Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 125. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 126. Key Challenges
Table 127. Market Risks
Table 128. Main Points Interviewed from Key Fibrodysplasia Ossificans Progressiva Drug Players
Table 129. Fibrodysplasia Ossificans Progressiva Drug Customers List
Table 130. Fibrodysplasia Ossificans Progressiva Drug Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Fibrodysplasia Ossificans Progressiva Drug Product Picture
Figure 2. Global Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Type in 2020 & 2026
Figure 3. LJPC-6417 Product Picture
Figure 4. Dipyridamole Product Picture
Figure 5. REGN-2477 Product Picture
Figure 6. Others Product Picture
Figure 7. Global Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Application in 2020 & 2026
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Research Center
Figure 11. Fibrodysplasia Ossificans Progressiva Drug Report Years Considered
Figure 12. Global Fibrodysplasia Ossificans Progressiva Drug Market Size 2015-2026 (US$ Million)
Figure 13. Global Fibrodysplasia Ossificans Progressiva Drug Sales 2015-2026 (K Pcs)
Figure 14. Global Fibrodysplasia Ossificans Progressiva Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Region (2015-2020)
Figure 16. Global Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Region in 2019
Figure 17. Global Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Region (2015-2020)
Figure 18. Global Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Region in 2019
Figure 19. Global Fibrodysplasia Ossificans Progressiva Drug Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Fibrodysplasia Ossificans Progressiva Drug Revenue in 2019
Figure 21. Fibrodysplasia Ossificans Progressiva Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Type (2015-2020)
Figure 23. Global Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Type in 2019
Figure 24. Global Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Type (2015-2020)
Figure 25. Global Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Type in 2019
Figure 26. Global Fibrodysplasia Ossificans Progressiva Drug Market Share by Price Range (2015-2020)
Figure 27. Global Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Application (2015-2020)
Figure 28. Global Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Application in 2019
Figure 29. Global Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Application (2015-2020)
Figure 30. Global Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Application in 2019
Figure 31. North America Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 32. North America Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Country in 2019
Figure 34. North America Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Country in 2019
Figure 35. U.S. Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 36. U.S. Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. Canada Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Fibrodysplasia Ossificans Progressiva Drug Market Share by Type in 2019
Figure 40. North America Fibrodysplasia Ossificans Progressiva Drug Market Share by Application in 2019
Figure 41. Europe Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 42. Europe Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Country in 2019
Figure 44. Europe Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Country in 2019
Figure 45. Germany Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 46. Germany Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. France Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. U.K. Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. Italy Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Russia Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Fibrodysplasia Ossificans Progressiva Drug Market Share by Type in 2019
Figure 56. Europe Fibrodysplasia Ossificans Progressiva Drug Market Share by Application in 2019
Figure 57. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 58. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Region in 2019
Figure 60. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Region in 2019
Figure 61. China Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 62. China Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. Japan Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. South Korea Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. India Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. Australia Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Taiwan Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Indonesia Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Thailand Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Malaysia Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Philippines Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Vietnam Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Market Share by Type in 2019
Figure 84. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Market Share by Application in 2019
Figure 85. Latin America Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 86. Latin America Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Country in 2019
Figure 88. Latin America Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Country in 2019
Figure 89. Mexico Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 90. Mexico Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Brazil Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Argentina Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Fibrodysplasia Ossificans Progressiva Drug Market Share by Type in 2019
Figure 96. Latin America Fibrodysplasia Ossificans Progressiva Drug Market Share by Application in 2019
Figure 97. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 98. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Revenue Market Share by Country in 2019
Figure 101. Turkey Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 102. Turkey Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Saudi Arabia Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. U.A.E Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Market Share by Type in 2019
Figure 108. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Market Share by Application in 2019
Figure 109. North America Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 110. North America Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. Europe Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Asia Pacific Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Latin America Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Middle East and Africa Fibrodysplasia Ossificans Progressiva Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
小売薬の世界市場（～2026年） A drug is any substance (other than food that provides nutritional support) that, when inhaled, injected, smoked, consumed, absorbed via a patch on the skin, or dissolved under the tongue causes a temporary physiological (and often psychological) change in the body. Increasing industry share of Asia…- ドラッグリポジショニングの世界市場（～2026年） Drug repurposing or re-profiling has been the hallmark to bring strong business growth and the trend is being followed by majority of the pharmaceutical and biopharmaceutical companies. Among all biologics approved in the U.S. during 2007-2009, 30-40% of them were the drugs repurposed or repositione…
- 乱用薬物検査サービスの世界市場（～2026年） Drug of Abuse Testing Services is the use of testing services to avoid the negative effects of drug abuse, to reduce the accidents. In addition to rise in number of substance abusers and increase in number of government initiatives to avoid ill effects of substance abuse at workplace & reduce number…
- 創薬の世界市場（～2026年） Drug discovery is the process by which new candidate medications are discovered. The pharmaceutical and biotech companies are increasing their collaboration with contract development and manufacturing organizations, thus playing a crucial role in the development and innovation of new drugs. Other fa…
- 創薬アウトソーシングの世界市場（～2026年） Over the last two decades, the Pharmaceutical industry has seen a radical change. The unprecedented downsizing of the internal discovery of big pharmaceuticals, patent expiration, shift towards biologics have seen a surge in the externalization and outsourcing activities. As the industry is looking …